TFF Pharmaceuticals investor relations material

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. The company is developing TFF-Pharma's lead product candidate, TFF-100, a pharmacologically active inhaled dry powder-based fibrosis therapy for the treatment of idiopathic pulmonary fibrosis (IPF) and cystic fibrosis. It owns and has control over the molecule (SMART-Breathe), formulation design, regulatory pathway data from previous phase 1 clinical trials in humans, development milestones and timelines, human safety data from phase 1 clinical trials that can be leveraged for future regulatory activities with health authorities worldwide for the development of the SMART-Breathe formulation for use in the treatment of IPF and CF. The company was founded in 2018 and is headquartered in Austin, Texas.